Beigene Ltd (BGNE)

$206.16

+14.05

(+7.31%)▲

Market is closed - opens 8 PM, 29 Nov 2024

Beigene Ltd Key Statistics

Market Capitalization
$22.6B
Revenue TTM
$23.5B
EBITDA
$-5.6B
Earnings Per Share (EPS)
$-8.18
Profit Margin
-25.5%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-23.22%

Beigene Ltd share price movements

  • $203.28
    $210.62
    $206.16
    downward going graph

    1.4%

    Downside

    Day's Volatility :3.48%

    Upside

    2.12%

    downward going graph
  • $126.97
    $248.16
    $206.16
    downward going graph

    38.41%

    Downside

    52 Weeks Volatility :48.84%

    Upside

    16.92%

    downward going graph

Beigene Ltd Returns

PeriodBeigene LtdSector (Health Care)Index (Russel 2000)
3 Months
3.86%
-5.9%
0.0%
6 Months
36.28%
3.8%
0.0%
1 Year
12.58%
13.3%
0.0%
3 Years
-39.93%
11.0%
-21.1%

Analyst Recommendation on Beigene Ltd

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Beigene Ltd(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast on Beigene Ltd

What analysts predicted

Upside of 34.64%

Current $206.16
Target $277.56

Insights on Beigene Ltd

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 634.40M → 1.00B (in $), with an average increase of 14.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -120.40M → -121.35M (in $), with an average decrease of 0.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 54.7% return, outperforming this stock by 42.1%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 40.4% return, outperforming this stock by 80.3%

Beigene Ltd Financials in INR & Dollars

FY18Y/Y Change
Revenue
198.2M
↓ 16.85%
Net Income
-673.8M
↑ 623.67%
Net Profit Margin
-339.91%
↓ 300.85%
FY19Y/Y Change
Revenue
428.2M
↑ 116.03%
Net Income
-950.6M
↑ 41.08%
Net Profit Margin
-221.99%
↑ 117.92%
FY20Y/Y Change
Revenue
308.9M
↓ 27.87%
Net Income
-1.6B
↑ 68.37%
Net Profit Margin
-518.18%
↓ 296.19%
FY21Y/Y Change
Revenue
1.2B
↑ 280.83%
Net Income
-1.4B
↓ 11.69%
Net Profit Margin
-120.15%
↑ 398.03%
FY22Y/Y Change
Revenue
1.4B
↑ 20.37%
Net Income
-2.0B
↑ 41.78%
Net Profit Margin
-141.52%
↓ 21.37%
FY23Y/Y Change
Revenue
2.5B
↑ 73.65%
Net Income
-881.7M
↓ 56.0%
Net Profit Margin
-35.86%
↑ 105.66%
Q2 FY23Q/Q Change
Revenue
595.3M
↑ 32.93%
Net Income
-381.1M
↑ 9.39%
Net Profit Margin
-64.03%
↑ 13.78%
Q3 FY23Q/Q Change
Revenue
781.3M
↑ 31.25%
Net Income
215.4M
↓ 156.52%
Net Profit Margin
27.57%
↑ 91.6%
Q4 FY23Q/Q Change
Revenue
634.4M
↓ 18.8%
Net Income
-367.6M
↓ 270.63%
Net Profit Margin
-57.94%
↓ 85.51%
Q1 FY24Q/Q Change
Revenue
751.7M
↑ 18.48%
Net Income
-251.2M
↓ 31.67%
Net Profit Margin
-33.41%
↑ 24.53%
Q2 FY24Q/Q Change
Revenue
929.2M
↑ 23.62%
Net Income
-120.4M
↓ 52.06%
Net Profit Margin
-12.96%
↑ 20.45%
Q3 FY24Q/Q Change
Revenue
1.0B
↑ 7.8%
Net Income
-121.4M
↑ 0.78%
Net Profit Margin
-12.12%
↑ 0.84%
FY18Y/Y Change
Total Assets
2.2B
↑ 114.98%
Total Liabilities
496.0M
↑ 36.93%
FY19Y/Y Change
Total Assets
1.6B
↓ 28.33%
Total Liabilities
633.9M
↑ 27.8%
FY20Y/Y Change
Total Assets
5.6B
↑ 247.38%
Total Liabilities
1.7B
↑ 173.14%
FY21Y/Y Change
Total Assets
8.6B
↑ 54.37%
Total Liabilities
2.4B
↑ 38.78%
FY22Y/Y Change
Total Assets
6.4B
↓ 26.22%
Total Liabilities
2.0B
↓ 16.94%
FY23Y/Y Change
Total Assets
5.8B
↓ 9.0%
Total Liabilities
2.3B
↑ 13.63%
Q2 FY23Q/Q Change
Total Assets
5.7B
↓ 3.83%
Total Liabilities
1.9B
↑ 7.26%
Q3 FY23Q/Q Change
Total Assets
5.5B
↓ 3.56%
Total Liabilities
1.8B
↓ 8.73%
Q4 FY23Q/Q Change
Total Assets
5.8B
↑ 5.08%
Total Liabilities
2.2B
↑ 26.8%
Q1 FY24Q/Q Change
Total Assets
5.7B
↓ 2.37%
Total Liabilities
2.3B
↑ 1.82%
Q2 FY24Q/Q Change
Total Assets
5.7B
↑ 0.79%
Total Liabilities
2.3B
↑ 3.15%
Q3 FY24Q/Q Change
Total Assets
5.8B
↑ 2.08%
Total Liabilities
2.4B
↑ 2.08%
FY18Y/Y Change
Operating Cash Flow
-547.7M
↓ 4395.15%
Investing Cash Flow
-637.6M
↑ 78.94%
Financing Cash Flow
1.7B
↑ 244.76%
FY19Y/Y Change
Operating Cash Flow
-750.3M
↑ 36.98%
Investing Cash Flow
554.2M
↓ 186.91%
Financing Cash Flow
85.7M
↓ 94.93%
FY20Y/Y Change
Operating Cash Flow
-1.3B
↑ 71.07%
Investing Cash Flow
-3.2B
↓ 671.74%
Financing Cash Flow
5.2B
↑ 5972.39%
FY21Y/Y Change
Operating Cash Flow
-1.3B
↑ 1.19%
Investing Cash Flow
640.7M
↓ 120.22%
Financing Cash Flow
3.6B
↓ 30.1%
FY22Y/Y Change
Operating Cash Flow
-1.5B
↑ 15.24%
Investing Cash Flow
1.1B
↑ 68.13%
Financing Cash Flow
-19.0M
↓ 100.52%
Q2 FY23Q/Q Change
Operating Cash Flow
-293.9M
↓ 47.87%
Investing Cash Flow
67.8M
↑ 0.0%
Financing Cash Flow
166.1M
↓ 935.92%
Q3 FY23Q/Q Change
Operating Cash Flow
-78.2M
↓ 73.41%
Investing Cash Flow
-186.3M
↓ 374.74%
Financing Cash Flow
-76.8M
↓ 146.23%

Beigene Ltd Technicals Summary

Sell

Neutral

Buy

Beigene Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Beigene Ltd Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beigene Ltd
Beigene Ltd
-4.79%
36.28%
12.58%
-39.93%
1.41%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.6%
-21.9%
-6.64%
15.35%
104.57%
Biontech Se
Biontech Se
5.89%
29.49%
21.63%
-66.7%
449.23%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-10.87%
72.69%
54.71%
40.39%
116.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.23%
5.31%
32.35%
144.36%
109.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beigene Ltd
Beigene Ltd
NA
NA
0.0
-5.68
-0.23
-0.1
NA
226.72
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.66
18.66
1.12
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beigene Ltd
Beigene Ltd
Buy
$22.6B
1.41%
NA
-25.5%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.0B
104.57%
18.66
33.61%
Biontech Se
Biontech Se
Buy
$28.9B
449.23%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
116.61%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.6B
109.5%
32.84
-4.51%

Beigene Ltd Institutional Holdings

  • Baker Bros Advisors LP

    9.95%

  • Capital Research & Mgmt Co - Division 3

    6.05%

  • Hillhouse Capital Advisors, Ltd.

    4.87%

  • PRIMECAP Management Company

    4.68%

  • Baillie Gifford & Co Limited.

    3.49%

  • Temasek Holdings Ltd.

    2.25%

Corporate Announcements

  • Beigene Ltd Earnings

    Beigene Ltd’s price-to-earnings ratio stands at None

    Read More

About Beigene Ltd

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Organization
Beigene Ltd
Employees
10600
CEO
Dr. Xiaobin Wu Ph.D.
Industry
Health Technology

FAQs